|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trial
|
|
Maria De Santis, MD, PhD
|
| Alicia Morgans interviews Maria De Santis on three studies: SunRISe-1 for NMIBC, AMBASSADOR on pembrolizumab, and VOLGA on ctDNA. Dr. De Santis highlights promising results for TAR-200 and emphasizes advancements in personalized bladder cancer treatment.
|
|
|
|
|
|
|
|
|
|
|
|
|
Event-Free Survival as Surrogate Endpoint in Muscle Invasive Bladder Cancer Research
|
|
Cora N. Sternberg, MD
|
| Cora Sternberg discusses her presentation on event-free survival (EFS) as a surrogate endpoint for overall survival in muscle-invasive bladder cancer. Dr. Sternberg explains the study's methodology, which analyzed 15 clinical trials evaluating neoadjuvant treatments followed by radical cystectomy.
|
|
|
|
|
|
|
|
|
|
|
|
|
Enfortumab Vedotin and Stereotactic Radiation Tested Before Surgery in Muscle-Invasive Bladder Cancer in STAR-EV Trial
|
|
Tian Zhang, MD, MHS
|
| Leslie Ballas and Tian Zhang discuss the STAR-EV trial, a new study combining enfortumab vedotin (EV) and radiation for muscle-invasive bladder cancer patients ineligible for cisplatin.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RECENT DATA FROM CONFERENCES WORLDWIDE |
|
|
|
| Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer (NIAGARA)
|
| Petros Grivas MD, PhD
|
| Petros Grivas reviewed the NIAGARA trial, which tested neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer (MIBC). While neoadjuvant chemotherapy is standard, its usage remains low.
|
|
|
|
|
|
| Identification of Bladder Cancer Patients That Could Benefit from Early Post-Cystectomy Immunotherapy Based on Serial Circulating Tumour DNA Testing: Preliminary Results from the TOMBOLA Trial
|
| Jørgen Bjerggaard Jensen, MD
|
| Jørgen Bjerggaard Jensen presented preliminary results from the TOMBOLA trial, assessing if serial circulating tumor DNA (ctDNA) testing can identify bladder cancer patients who would benefit from early post-cystectomy immunotherapy.
|
|
|
|
|
|
| First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab Nab-Paclitaxel Followed by Postsurgical Adjuvant Nivolumab in Patients with Muscle-Invasive Bladder Cancer
|
| Chiara Mercinelli, MD
|
| Chiara Mercinelli presented the NURE-Combo trial results, a phase 2 study of neoadjuvant nivolumab plus nab-paclitaxel in muscle-invasive bladder cancer (MIBC). The findings suggest this combination is a safe, effective strategy for cisplatin-ineligible patients, potentially supporting organ-sparing approaches.
|
|
|
|
|
|
|
|
|
|
|
| Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy
|
| Cora N. Sternberg, MD
|
| Cora N. Sternberg presented a study evaluating event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) post-neoadjuvant therapy. Analyzing 15 clinical trials, the results showed a strong association (R²=0.94) between EFS and OS, supporting EFS as a valuable interim measure in treatment evaluations.
|
|
|
|
|
|
| First Results of the Phase Ib-II BladderGATE Clinical Trial: Intravenous Atezolizumab + Intravesical BCG Upfront Combination in BCG-Naïve High Risk Non-Muscle Invasive Bladder Cancer Patients
|
| Felix Guerrero-Ramos, MD, PhD, FEBU
|
| Felix Guerrero-Ramos presented the BladderGATE trial results, evaluating intravenous atezolizumab combined with intravesical BCG in high-risk NMIBC patients. With a median follow-up of 31.5 months, the 2-year high-grade bladder recurrence-free survival rate was 83.2%, indicating that this combination is both feasible and safe for further study
|
|
|
|
|
|
